Quilseconazole (VT-1129) is a selective, orally available fungal CYP51 (lanosterol 14-α-demethylase) inhibitor.
Quilseconazole displays greater selectivity for fungal enzyme than for mammalian CYP450 compared to the approved azole class of antifungal drugs.
Quilseconazole inhibits C. albicans and T. rubrum with MIC of <0.001 ug/mL, also demonstrated potent activities against Cryptococcusspecies as demonstrated by low MIC50 and MIC90 values.
